Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| natural killer cell | 11 studies | 18% ± 2% | |
| CD16-positive, CD56-dim natural killer cell, human | 8 studies | 20% ± 3% | |
| CD16-negative, CD56-bright natural killer cell, human | 7 studies | 19% ± 4% | |
| CD8-positive, alpha-beta T cell | 5 studies | 18% ± 2% | |
| gamma-delta T cell | 5 studies | 21% ± 8% | |
| effector memory CD8-positive, alpha-beta T cell | 4 studies | 17% ± 1% | |
| regulatory T cell | 4 studies | 18% ± 3% | |
| CD8-positive, alpha-beta memory T cell | 4 studies | 20% ± 1% | |
| CD4-positive, alpha-beta T cell | 3 studies | 18% ± 2% | |
| mature NK T cell | 3 studies | 18% ± 2% | |
| naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 17% ± 1% | |
| plasma cell | 3 studies | 25% ± 9% | |
| epithelial cell | 3 studies | 23% ± 6% | |
| B cell | 3 studies | 17% ± 0% | |
| dendritic cell | 3 studies | 25% ± 3% | |
| double negative thymocyte | 3 studies | 20% ± 7% | |
| memory B cell | 3 studies | 15% ± 0% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| peripheral blood | 3 studies | 19% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 469.20 | 1445 / 1445 | 100% | 30.61 | 183 / 183 |
| liver | 100% | 493.62 | 226 / 226 | 100% | 35.37 | 406 / 406 |
| ovary | 100% | 551.77 | 180 / 180 | 100% | 33.96 | 430 / 430 |
| pancreas | 100% | 538.64 | 328 / 328 | 100% | 43.36 | 178 / 178 |
| skin | 100% | 802.79 | 1809 / 1809 | 100% | 50.35 | 472 / 472 |
| lung | 100% | 587.56 | 578 / 578 | 100% | 38.44 | 1153 / 1155 |
| prostate | 100% | 489.90 | 245 / 245 | 100% | 40.85 | 501 / 502 |
| uterus | 100% | 508.20 | 170 / 170 | 100% | 45.63 | 458 / 459 |
| brain | 100% | 544.72 | 2635 / 2642 | 100% | 41.97 | 705 / 705 |
| thymus | 100% | 450.09 | 652 / 653 | 100% | 47.25 | 604 / 605 |
| kidney | 100% | 431.15 | 89 / 89 | 100% | 31.86 | 898 / 901 |
| stomach | 100% | 477.03 | 359 / 359 | 100% | 46.26 | 285 / 286 |
| intestine | 100% | 625.10 | 966 / 966 | 100% | 51.75 | 525 / 527 |
| adrenal gland | 100% | 479.44 | 258 / 258 | 100% | 48.63 | 229 / 230 |
| breast | 100% | 549.19 | 459 / 459 | 100% | 41.37 | 1113 / 1118 |
| bladder | 100% | 503.00 | 21 / 21 | 99% | 46.65 | 500 / 504 |
| adipose | 100% | 527.04 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 51.39 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 99.15 | 29 / 29 |
| spleen | 100% | 1238.21 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 44.56 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 28.91 | 1 / 1 |
| blood vessel | 100% | 553.11 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 100% | 966.23 | 926 / 929 | 0% | 0 | 0 / 0 |
| muscle | 100% | 365.93 | 799 / 803 | 0% | 0 | 0 / 0 |
| heart | 98% | 327.44 | 843 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0000398 | Biological process | mRNA splicing, via spliceosome |
| GO_0016567 | Biological process | protein ubiquitination |
| GO_0070100 | Biological process | negative regulation of chemokine-mediated signaling pathway |
| GO_0006281 | Biological process | DNA repair |
| GO_0034247 | Biological process | snoRNA splicing |
| GO_0016607 | Cellular component | nuclear speck |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0071005 | Cellular component | U2-type precatalytic spliceosome |
| GO_0005684 | Cellular component | U2-type spliceosomal complex |
| GO_0005634 | Cellular component | nucleus |
| GO_0061630 | Molecular function | ubiquitin protein ligase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0046872 | Molecular function | metal ion binding |
| Gene name | RNF113A |
| Protein name | E3 ubiquitin-protein ligase RNF113A (EC 2.3.2.27) (Cwc24 homolog) (RING finger protein 113A) (Zinc finger protein 183) |
| Synonyms | ZNF183 RNF113 |
| Description | FUNCTION: Required for pre-mRNA splicing as component of the spliceosome . As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable). E3 ubiquitin-protein ligase that catalyzes the transfer of ubiquitin onto target proteins . Catalyzes polyubiquitination of SNRNP200/BRR2 with non-canonical 'Lys-63'-linked polyubiquitin chains . Plays a role in DNA repair via its role in the synthesis of 'Lys-63'-linked polyubiquitin chains that recruit ALKBH3 and the ASCC complex to sites of DNA damage by alkylating agents . Ubiquitinates CXCR4, leading to its degradation, and thereby contributes to the termination of CXCR4 signaling . . |
| Accessions | O15541 ENST00000371442.4 |